P0035
Penciclovir
别名:
2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6H-purin-6-one, BRL-39123
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C10H15N5O3
化学文摘社编号:
分子量:
253.26
NACRES:
NA.76
PubChem Substance ID:
UNSPSC Code:
51102829
MDL number:
InChI key
JNTOCHDNEULJHD-UHFFFAOYSA-N
SMILES string
NC1=NC(=O)c2ncn(CCC(CO)CO)c2N1
InChI
1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
form
powder
solubility
0.02 M potassium phosphate: soluble 2 mg/mL
antibiotic activity spectrum
viruses
mode of action
DNA synthesis | interferes
enzyme | inhibits
Quality Level
正在寻找类似产品? 访问 产品对比指南
Application
Penciclovir is a selective antiherpesvirus agent, particularly against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and varicella-zoster virus (VZV).
Biochem/physiol Actions
Penciclovir is converted to its active form, penciclovir triphosphate, by cellular kinases. It inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. It inhibits DNA synthesis of virus-infected cells. Penciclovir has in vitro activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). It does not inhibit DNA synthesis in non-infected cells. Mode of resistance is via qualitative changes in viral thymidine kinase or DNA polymerase.
Other Notes
Keep container tightly closed in a dry and well-ventilated place.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
D L Earnshaw et al.
Antimicrobial agents and chemotherapy, 36(12), 2747-2757 (1992-12-01)
The metabolism and mode of action of penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; BRL 39123] were studied and compared with those of acyclovir. In uninfected MRC-5 cells, low concentrations of the triphosphates of penciclovir and acyclovir were occasionally just detectable, the limit of detection
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.
Teresa H Bacon et al.
Clinical microbiology reviews, 16(1), 114-128 (2003-01-15)
Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections. In spite of the distribution of over 2.3 x 10(6) kg of these nucleoside analogues, the prevalence of acyclovir resistance
Qingzhi Lv et al.
International journal of pharmaceutics, 372(1-2), 191-198 (2009-05-12)
The objective of this investigation was to develop solid lipid nanoparticles (SLNs) of penciclovir and evaluate the potential of SLNs as the carrier of penciclovir for topical delivery. Penciclovir-loaded SLNs were prepared by a double (W/O/W) emulsion technique. The SLNs
Weiwei Zhu et al.
International journal of pharmaceutics, 378(1-2), 152-158 (2009-05-26)
The purpose of this study was to investigate microemulsion-based hydrogel (MBH) as a topical delivery system for penciclovir. Topical delivery of penciclovir in the forms of microemulsion, MBH and the commercial cream was evaluated in vitro and in vivo. The
Jocelyne Piret et al.
Antimicrobial agents and chemotherapy, 55(2), 459-472 (2010-11-17)
Herpes simplex viruses (HSV) type 1 and type 2 are responsible for recurrent orolabial and genital infections. The standard therapy for the management of HSV infections includes acyclovir (ACV) and penciclovir (PCV) with their respective prodrugs valacyclovir and famciclovir. These
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持